CTOs on the Move

Eli Lilly and Company

www.lilly.com

 
Lilly makes medicines that help people live longer, healthier, more active lives. We were founded by Eli Lilly in 1876, and are now the 10th largest pharmaceutical company in the world. We have steadfastly remained independent, but not isolated. Across the globe, Lilly has developed productive alliances and partnerships that advance our capacity to develop innovative medicines at lower costs. Lilly is consistently ranked as one of the best companies in the world to work for, and generations of Lilly employees have sustained a culture that values excellence, integrity, and respect for people. We make medicines that help people live longer, healthier, ...
  • Number of Employees: 10K-50K
  • Annual Revenue: > $1 Billion

Executives

Name Title Contact Details
Larry McCubbin
 Information Technology Director - Security Operations and Identity Management Profile
Marc Othersen
 Chief Information Security Officer Profile
Aarti Shah
 Chief Information Officer Profile
Ina Kamenz
 Chief Information Officer Profile
Mike Meadows
 Chief Technology Officer Profile

Similar Companies

Ferrer Therapeutics

Ferrer Therapeutics is a Lake Hiawatha, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Rhoads Pharmacy

Rhoads Pharmacy is a Hummelstown, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

VioQuest Pharmaceuticals

VioQuest Pharmaceuticals is a Basking Ridge, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Redox Pharmaceutical

Redox Pharmaceutical Corp. is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Paratek Pharmaceuticals

Paratek Pharmaceuticals is focused on the discovery, development, and commercialization of medicines designed to save lives and alleviate suffering. Our lead product candidate, omadacycline, is the first in a new class of tetracyclines known as aminomethycyclines, with broad spectrum activity against Gram-positive, Gram-negative and atypical bacteria. Omadacycline is being developed as a once daily, oral and intravenous, empiric monotherapy for community acquired bacterial infections, particularly when antibiotic resistance is of concern.